ME/CFS vs Gulf War Illness: symptoms, biomarkers, trials and research
A data-driven comparison of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) and Gulf War Illness built from the Open Source Medicine Foundation biomarker atlases, PubMed literature feeds, ClinicalTrials.gov registry extract and post-acute infection syndrome (PAIS) cohort database.
GWI and ME/CFS have been compared head-to-head in VA-funded studies for decades, sharing fatigue, pain, cognitive symptoms and reported mitochondrial and cholinergic abnormalities. Several registered GWI trials recruit under a chronic fatigue syndrome label.
What each condition is
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Also known as: CFS, ME, Systemic Exertion Intolerance Disease
ME/CFS is a chronic, multi-system illness defined clinically by a substantial reduction in activity, post-exertional malaise (PEM), unrefreshing sleep and either cognitive impairment or orthostatic intolerance. It frequently begins after an infection, including mononucleosis (EBV), SARS, Q fever, Ross River virus and now SARS-CoV-2, but many cases have no identified trigger. There is no validated diagnostic test; research biomarkers centre on energy metabolism, immune signalling and autonomic function.
Atlas scope: Molecular, metabolic, immunological, and autonomic alterations in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) compared to healthy sedentary and active controls — including post-exertional malaise (PEM) phenotypes.
OSMF resources: biomarker atlas · literature feed
Gulf War Illness
Also known as: GWI, Gulf War Syndrome, Chronic Multisymptom Illness
Gulf War Illness is a chronic multisymptom condition affecting roughly a quarter to a third of the nearly 700,000 US and allied personnel deployed in the 1990-1991 Gulf War. It is defined by the Kansas or CDC criteria (fatigue, pain, cognitive and mood symptoms, gastrointestinal and respiratory complaints) rather than by a single exposure, though pyridostigmine bromide, pesticides and low-level nerve agents are the leading hypotheses. Unlike the other conditions compared here it has no infectious trigger, which makes its biomarker overlap with post-viral syndromes scientifically interesting.
Atlas scope: Inflammatory, autoimmune, metabolic, cholinergic, and exposure-related biomarker alterations in Gulf War Illness (GWI / chronic multisymptom illness) compared to healthy deployed and non-deployed Gulf War veterans.
OSMF resources: biomarker atlas · literature feed
Side-by-side summary
| Measure | ME/CFS | Gulf War Illness |
|---|---|---|
| Biomarkers catalogued | 46 | 41 |
| Biomarker categories covered | inflammatory (10), metabolic (10), autonomic (6), immune (5), mitochondrial (4), functional (4), autoimmune (3), neurological (2), urinary (2) | inflammatory (10), metabolic (8), exposure (7), autoimmune (5), neurological (4), functional (3), autonomic (2), ocular (2) |
| Markers with LOINC codes | 13 | 12 |
| Literature studies tracked | 75 | 75 |
| Most recent tracked study | 06 Jul 2026 | 25 Jun 2026 |
| Registered trials (all statuses) | 146 | 4 |
| Recruiting / not yet recruiting | 26 | 0 |
| Active, not recruiting | 9 | 0 |
| Completed | 75 | 4 |
| Terminated / withdrawn / suspended | 15 | 0 |
| Unknown status | 21 | 0 |
| Named cohorts in PAIS database | 3 | 0 |
| Therapeutic agents tracked | 179 | 10 |
Trial condition matching: ME/CFS uses the registry’s mapped condition label; Gulf War Illness uses keyword matching on registry condition and title fields. Trials listing both conditions: 3.
Shared biomarkers (13)
Markers catalogued in both atlases, matched by normalised name or LOINC code. Rows marked direction differs are reported to change in opposite or inconsistent directions across the two literatures, which may reflect different comparison groups, assays or disease stages rather than true biology.
| Biomarker | Category | Direction in ME/CFS | Direction in Gulf War Illness | Matched by | Sources |
|---|---|---|---|---|---|
| Interleukin-1 (IL-1α/β) Interleukin-1β (IL-1β) in Gulf War Illness | inflammatory | Increased vs HC | Increased vs HGV | LOINC 26864-3 | Corbitt et al. 2019; Johnson et al. 2016 |
| Tumor Necrosis Factor-α (TNF-α) direction differs | inflammatory | Mixed / conflicting vs HC | Increased vs HGV | LOINC 3074-8 | Corbitt et al. 2019; Johnson et al. 2016 |
| Interleukin-6 (IL-6) direction differs | inflammatory | Mixed / conflicting vs HC | Increased vs HGV | LOINC 26881-5 | Corbitt et al. 2019; Johnson et al. 2016 |
| Interleukin-8 (IL-8 / CXCL8) direction differs | inflammatory | Mixed / conflicting vs HC | Increased vs HGV | LOINC 26998-9 | Corbitt et al. 2019; Johnson et al. 2016 |
| C-Reactive Protein (CRP) direction differs | inflammatory | Mixed / conflicting vs HC | Increased vs HGV | LOINC 1988-5 | Strawbridge et al. 2019; Johnson et al. 2016 |
| Acylcarnitines (composite) Acylcarnitines in Gulf War Illness | metabolic | Increased vs HC | Increased vs HGV | name | Jinushi et al. 2023; Gean et al. 2021 |
| Lactate (blood) Lactate in Gulf War Illness | metabolic | Increased vs HC | Increased vs HGV | LOINC 2524-7 | Holden et al. 2020; Gean et al. 2021 |
| β2-adrenergic receptor autoantibodies | autoimmune | Increased vs HC | Increased vs HGV | name | Maksoud et al. 2023; Gean et al. 2021 |
| Heart rate variability (RMSSD) Heart rate variability (HRV) in Gulf War Illness | autonomic | Decreased vs HC | Decreased vs HGV | name | Nelson et al. 2019; Gean et al. 2021 |
| Orthostatic heart rate increment | autonomic | Increased vs HC | Increased vs HGV | name | Nelson et al. 2019; Gean et al. 2021 |
| Cortisol (diurnal rhythm) Cortisol (diurnal) in Gulf War Illness | neurological | Mixed / conflicting vs HC | Mixed / conflicting vs HGV | LOINC 2143-6 | Maksoud et al. 2023; Gean et al. 2021 |
| 6-minute walk distance | functional | Decreased vs HC | Decreased vs HGV | name | Maksoud et al. 2023; Gean et al. 2021 |
| sCD14 | inflammatory | Increased vs HC | Increased vs HGV | LOINC 30180-5 | Saito et al. 2024; Gean et al. 2021 |
Distinct biomarkers
Top 15 markers catalogued for one condition but not matched in the other. Full lists are on the ME/CFS atlas and the Gulf War Illness atlas.
Only in ME/CFS atlas (33)
- Transforming Growth Factor-β (TGF-β) Increased inflammatory
- Interleukin-10 (IL-10) Mixed / conflicting inflammatory
- Leptin Increased inflammatory
- Resistin Mixed / conflicting inflammatory
- C16 Acylcarnitine (palmitoylcarnitine) Increased metabolic
- C18 Acylcarnitine (stearoylcarnitine) Increased metabolic
- Free carnitine Mixed / conflicting metabolic
- ATP production capacity Decreased mitochondrial
- Mitochondrial membrane potential Decreased mitochondrial
- Pyruvate dehydrogenase activity Decreased mitochondrial
- Oxidative phosphorylation efficiency Decreased mitochondrial
- Serine Decreased metabolic
- Sarcosine Decreased metabolic
- Kynurenine Increased metabolic
- NK cell cytotoxicity Decreased immune
+18 more in the atlas.
Only in Gulf War Illness atlas (28)
- Neopterin Increased inflammatory
- sCD26 (soluble DPPIV) Mixed / conflicting inflammatory
- Homocysteine Increased metabolic
- Interferon-γ (IFN-γ) Increased inflammatory
- Glutathione (GSH) Decreased metabolic
- GSH:GSSG ratio Decreased metabolic
- 8-isoprostane Increased metabolic
- Coenzyme Q10 Decreased metabolic
- PON1 (paraoxonase 1) activity Decreased exposure
- PON1 Q192R polymorphism Mixed / conflicting exposure
- Butyrylcholinesterase (BChE) Mixed / conflicting exposure
- Acetylcholinesterase (AChE) Mixed / conflicting exposure
- Anti-acetylcholine receptor antibodies Increased autoimmune
- Anti-nuclear antibodies (ANA) Mixed / conflicting autoimmune
- Rheumatoid factor (RF) Mixed / conflicting autoimmune
+13 more in the atlas.
Overlapping therapeutics under investigation (8)
Agents that appear in registered trials or the OSMF therapeutic-agent database for both ME/CFS and Gulf War Illness. Inclusion means an agent is being studied, not that it works.
- Acupressure Treatment
- Coenzyme Q10 (CoQ10)
- Cognitive Behavioral Therapy
- Graded Dobutamine Infusions
- Graded Phenylephrine Injections
- Metformin
- Nasal Cpap Treatment During Sleep
- Reiki
Trials enrolling both conditions (3)
- NCT02075489 · Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans (Completed)
- NCT00252629 · Sleep Disordered Breathing in Gulf War Illness and the Effect of Nasal CPAP Treatment (Completed)
- NCT00100412 · Hyporeactivity and Gulf War Illness (Completed)
Research cohorts
ME/CFS cohorts (3)
- DecodeME ME/CFS GWAS registry linkage, n=15,579, biobank active
- UK ME/CFS Biobank (CureME, LSHTM) cross sectional, n=632, biobank active
- NIH Intramural ME/CFS Deep-Phenotyping Study (Walitt/Nath 2024) cross sectional, n=57, biobank active
Gulf War Illness cohorts (0)
No named cohort for this condition in the PAIS database yet.
Recent research
Latest ME/CFS studies
Latest Gulf War Illness studies
Frequently asked questions
Can you have both ME/CFS and Gulf War Illness?
They are not mutually exclusive. Both are diagnosed clinically, and a person can meet criteria for ME/CFS and Gulf War Illness at the same time. In the OSMF data the two conditions share 13 catalogued biomarkers, 3 registered trials list both conditions, and 0 cohorts in the PAIS database are relevant to both. Overlap in a dataset is not evidence that one condition causes the other.
How do the biomarker profiles differ?
ME/CFS has 46 catalogued markers, led by inflammatory (10), metabolic (10), autonomic (6). Gulf War Illness has 41, led by inflammatory (10), metabolic (8), exposure (7). 13 markers appear in both atlases, and 4 of those are reported to move in different directions (Tumor Necrosis Factor-α (TNF-α), Interleukin-6 (IL-6), Interleukin-8 (IL-8 / CXCL8)...). Categories unique to ME/CFS: immune, mitochondrial, urinary; unique to Gulf War Illness: exposure, ocular.
Which has more active clinical trials?
ME/CFS has more: 35 active or recruiting trials versus 0 for Gulf War Illness (registry snapshot 07 Oct 2026). Totals including completed, terminated and unknown-status studies are 146 for ME/CFS and 4 for Gulf War Illness. Condition matching for Gulf War Illness relies on keyword matching of registry condition fields and may miss trials. Trial counts measure research attention, not treatment efficacy.
Which condition has more recent research?
OSMF tracks 75 recent PubMed-indexed studies for ME/CFS (latest 06 Jul 2026) and 75 for Gulf War Illness (latest 25 Jun 2026). The feeds hold a rolling window of recent publications, so they indicate current publication pace rather than lifetime output. See the ME/CFS feed and the Gulf War Illness feed for the full lists.
Are the same treatments being studied for both?
8 agents appear in the trial registry or therapeutic-agent database for both conditions, including Acupressure Treatment, Coenzyme Q10 (CoQ10), Cognitive Behavioral Therapy, Graded Dobutamine Infusions, Graded Phenylephrine Injections. All of these are investigational for these indications; none is an approved treatment for either condition. Overlap usually reflects shared hypotheses (immune modulation, autonomic support, antiviral or anti-inflammatory strategies) rather than demonstrated efficacy.
Which has larger research cohorts?
The PAIS cohort database lists 3 named cohorts for ME/CFS and 0 named cohorts for Gulf War Illness, the largest being DecodeME ME/CFS GWAS (15,579 enrolled). Cohorts with stored biospecimens and open external access are the most useful for cross-condition biomarker validation.
Related comparisons
Cite this page
@misc{osmf_mecfs_vs_gulfwarillness,
author = {Open Source Medicine Foundation},
title = {ME/CFS vs Gulf War Illness: symptoms, biomarkers, trials and research compared},
year = {2026},
howpublished = {\url{https://research.opensourcemed.info/compare/me-cfs-vs-gulf-war-illness.html}},
note = {Data as of 2026-10-07}
}Get OSMF research updates
New biomarker, trial and cohort data, summarised for patients and researchers.
Last updated 07 Oct 2026 (page build). Underlying data: literature feeds 06 Jul 2026 / 09 Jul 2026; trial registry 07 Oct 2026; atlases 29 Jun 2026 / 29 Jun 2026. Generated by scripts/build_compare_pages.py.